I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

I am a healthcare professional in the United States

Required field.

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.

Leave site
Home ECTRIMS 2023
Roche and Genentech at

ECTRIMS 2023

October 11 - October 13
Milan, Italy / Virtual (Hybrid)
ectrims.eu
-
Medical Materials
Agenda
Coming soon
11:45 AM
Duration 5mins Milan, Italy
Booth Talk: Early use of high-efficacy therapies: What is holding us back?
Dr Wallace Brownlee
Neuroscience | Multiple Sclerosis
Share page
02:30 PM
Duration 120mins Milan, Italy
Patterns of referral from primary care physicians to specialists among people with multiple sclerosis or related disorders
Anisha M Patel, Elizabeth S. Mearns, Kimberly Jinnett, Abhishek Gaur, Bryan R. Cobb, Christine J. Macaluso, Jonathan M. Weiss, David E. Jones, Nikki Win
Neuroscience | Multiple Sclerosis
Share page
Duration 120mins Milan, Italy
Teleneurology visits for multiple sclerosis had lower rates of orders and similar rates of emergency department utilisation compared with in-person visits
Kaitlyn N. Palmer, MD, Daniel Ontaneda, MD, PhD, Tucker Harvey, Anisha M. Patel, PhD, Elizabeth S. Mearns, PharmD, Nikki Win, PhD, Bryan R. Cobb, PhD, Steve Roush, PharmD, Marisa McGinley, DO
Neuroscience | Multiple Sclerosis
Share page
Duration 120mins Milan, Italy
Multiple sclerosis: a path to unravelling disease complexity with multidimensional quantitative analytics incorporating digital tools for phenotyping both spatiotemporal gait parameters and cognition domains
O Kaczmarek, S Baek,1 J Weller, B Cameron, C Cousin, ES Mearns, J Priest, G Seth, T McIver, BR Cobb, N Win, and M Gudesblatt
Neuroscience | Multiple Sclerosis
Share page
Duration 120mins Milan, Italy
Satralizumab▼ Treatment in Adults With AQP4-IgG–Seropositive Neuromyelitis Optica Spectrum Disorder: A Retrospective Case Series
Hesham Abboud, Brian Steingo, Diana Vargas, Julie Patel, Nancy Nealon, Mary Alissa Willis, Yang Mao-Draayer, Dmitry Khaitov, Jose Avila Ornelas, Adnan Subei, Clifford Reed, William S. Baek, Michelle Tsai, Angie Kim, Ahmed Z. Obeidat, Krupa Pandey, Michael Levy, Negar Molazadeh, Robert Shin, Rebecca Romero, Paige Goulette, Rosemarie Walch, Jeanie Coté, Robert Pace, Buse Sengul, Lisa Ferayorni, Shervin Gholizadeh
Neuroscience | Neuromyelitis Optica
Share page
Duration 120mins Milan, Italy
Addressing the Burdens of Neuromyelitis Optica Spectrum Disorders Amid Challenges of the COVID-19 Pandemic: Real-World Perspectives From Patients
Patel AM, Martin A, Perkowski K, Olsen P, Gholizadeh S, Behne J, Behne MK, Jackson-Matthews K, McDaniel L, Woolf C, Yeaman MR
Neuroscience | Neuromyelitis Optica
Share page
Duration 120mins Milan, Italy
Safety of Ocrelizumab in Multiple Sclerosis: Updated Analysis in Patients with Relapsing and Primary Progressive Multiple Sclerosis
Hauser SL, Kappos L, Montalban X, Chognot C, Pasquarelli N, Kadner K, Pradhan A, Incera E, Wolinsky JS, El Azzouzi B
Neuroscience | Multiple Sclerosis
Share page
Duration 120mins Milan, Italy
The Patient Impact of 10 Years of Ocrelizumab Treatment in Multiple Sclerosis: Long-Term Data From the Phase III OPERA and ORATORIO Studies
Weber MS, Kappos L, Hauser SL, Nicholas JA, Schneble HM, Wang Q, Giovannoni G, Filippi M
Neuroscience | Multiple Sclerosis
Share page
Duration 120mins Milan, Italy
Pregnancy and Infant Outcomes in Women Receiving Ocrelizumab for the Treatment of Multiple Sclerosis: Analysis of the Largest Available Outcomes Database
Hellwig K, Oreja-Guevara C, Vukusic S, Pietrasanta C, McElrath T, Dobson R, Craveiro L, Ferreira G, Lin CJ, Pasquarelli N, Zecevic D, Bove R
Neuroscience | Multiple Sclerosis
Share page
Duration 120mins Milan, Italy
Ocrelizumab Dose Selection for Treatment of Paediatric Relapsing-Remitting Multiple Sclerosis: Preliminary Pharmacokinetic, Safety and Efficacy Results From the OPERETTA I Study
Valeriani M, Mar S, Steinborn B, Schreiner T, Waubant E, Filippi M, Kotulska K, Mazurkiewicz-Beldzinska M, Manilus C, Kletzl H, Lin C-J, El Azzouzi B, Hogea A, E Peill, Banwell B
Neuroscience | Multiple Sclerosis
Share page
Duration 120mins Milan, Italy
Composite Confirmed Disability Worsening is a Useful Clinical Trial Endpoint for Multiple Sclerosis Focusing on Disability Progression
Kappos L, Yiu S, Cutter G, Coetzee T, Bonati U, Yuen S, Dahlke F, Lublin F
Neuroscience | Multiple Sclerosis
Share page
Duration 120mins Milan, Italy
Combining Measures From Clinical Assessments, Imaging and Fluid Biomarkers at 1 Year to Predict Multiple Sclerosis Progression at 2 Years
Lewin-Koh N, Clayton D, Berge C, Dahlke F, Schneble H-M, Bernasconi C
Neuroscience | Multiple Sclerosis
Share page
Duration 120mins Milan, Italy
Long-term efficacy of satralizumab▼ in patients with AQP4-IgG+ NMOSD: Updated analysis from the open-label SAkuraMoon study
Jacqueline Palace, Anthony Traboulsee, Albert Saiz, Jerome De Seze, Ingo Kleiter, Jeffrey L. Bennett, Daniela Stokmaier, Gaëlle Klingelschmitt, Audrey Yeo Te-ying, Ivana Vodopivec, Takashi Yamamura
Neuroscience | Neuromyelitis Optica
Share page
Duration 120mins Milan, Italy
Infection in NMOSD: An analysis of the patterns of infections in SAkuraMoon (an open-label study to evaluate the long-term safety and efficacy of satralizumab▼) with post-marketing data and US-based health claims data
Benjamin M. Greenberg, Kazuo Fujihara, Brian Weinshenker, Francesco Patti, Ingo Kleiter, Jeffrey L. Bennett, Jacqueline Palace, Miriam Triyatni, Kathleen Blondeau, Alexander Burdeska, Innocent Ngwa, Gaëlle Klingelschmitt, Takashi Yamamura
Neuroscience | Neuromyelitis Optica
Share page
Duration 120mins Milan, Italy
Smartphone-Based Passive Monitoring of Gait in People with Progressive Multiple Sclerosis
Marco Ganzetti, Lito Kriara, Mattia Zanon, Mike D Rinderknecht, Stanislas Hubeaux, Florian Lipsmeier, Letizia Leocani, Marisa P McGinley, Maria Pia Sormani, Giancarlo Comi, Hemut Butzkueven, Licinio Craveiro
Neuroscience | Multiple Sclerosis
Share page
Duration 120mins Milan, Italy
Subcutaneous Ocrelizumab in Patients with Multiple Sclerosis: Results of the Phase Ib Dose-Finding OCARINA I Study
Newsome SD, Goldstick L, Townsend B, Figueiredo C, Wolf C,4 Bortolami O, Kletzl H, Bursic L, Schmidt J, Clinch S, Tessaro F, Zecevic D, Bermel R
Neuroscience | Multiple Sclerosis
Share page
Duration 120mins Milan, Italy
Subcutaneous Ocrelizumab in Patients with Multiple Sclerosis: Results of the Phase III OCARINA II Study
Newsome SD, Krzystanek E, Selmaj K, Figueiredo C, Wolf C, Schneble H-M, Bortolami O, Kletzl H, Bursic L, Zecevic D, Centonze D
Neuroscience | Multiple Sclerosis
Share page
Duration 120mins Milan, Italy
Reduction of intrathecal immunoglobulin levels with ocrelizumab treatment in relapsing and primary progressive multiple sclerosis
Martin S. Weber, Jeffrey M. Gelfand, Amit Bar-Or, Briana Cameron, Akshaya Ramesh, Veronica Anania, H. Christian von Büdingen, Ann E. Herman, David Spiciarich, Katja Grondey, Konstantin Schüetz, Ryan C. Winger, Xiaoming Jia, Christopher Harp, Anne H. Cross
Neuroscience | Multiple Sclerosis
Share page
Duration 120mins Milan, Italy
Cerebrospinal fluid neurofilament heavy levels correlate with spinal cord lesions and disability in multiple sclerosis
Yun-An Shen, Christopher Harp, H-Christian von Büdingen, Ann Herman, Jenny Jiang, Nicolas Strauli, Stephen L Hauser, Bruce AC Cree, Xiaoming Jia
Neuroscience | Multiple Sclerosis
Share page
Duration 120mins Milan, Italy
One-year analysis of efficacy and safety data from Black and Hispanic patients with relapsing multiple sclerosis receiving ocrelizumab treatment in the CHIMES trial
Mitzi Williams, Timothy Vartanian, Anthony Reder, Nancy Monsoon, Krupa Pandey, Kottil Rammohan, Barry Hendin, Diraj Sokhi, Lilyana Amezcua, Evanthia Bernitsas, Rikisha Parekh, Jinglan Pei, Ibraheem Abioye, Juan Acosta, Gregory Wu
Neuroscience | Multiple Sclerosis
Share page
Duration 120mins Milan, Italy
Clarification of blood-retinal barrier on AQP4-peptide immunized mice
Yoshichika Katsura, Kenichi Serizawa, Haruna Tomizawa-Shinohara, Shota Miyake, Yoshihiro Matsumoto, Mariko Noguchi-Sasaki
Neuroscience | Neuromyelitis Optica
Share page
Duration 120mins Milan, Italy
Relapse under the prescription of satralizumab▼ in neuromyelitis optica spectrum disorder: Analysis of a Japanese claims database
Jin Nakahara, Ichiro Nakashima, Hideo Yasunaga, Masami Yamashita, Nobuo Nishijima, Atsushi Satomura, Mariko Nio, Kazuo Fujihara
Neuroscience | Neuromyelitis Optica
Share page
Duration 120mins Milan, Italy
Use of immunosuppressive therapy among patients with NMOSD using satralizumab▼ treatment: A study based on Japanese real-world data
Jin Nakahara, Ichiro Nakashima, Hideo Yasunaga, Masami Yamashita, Nobuo Nishijima, Atsushi Satomura, Mariko Nio, Kazuo Fujihara
Neuroscience | Neuromyelitis Optica
Share page
Duration 120mins Milan, Italy
Watch Prof Newsome discuss: Subcutaneous Ocrelizumab in Patients with Multiple Sclerosis: Results of the Phase III OCARINA II Study
Newsome SD, Krzystanek E, Selmaj K, Figueiredo C, Wolf C, Schneble H-M, Bortolami O, Kletzl H, Bursic L, Zecevic D, Centonze D
Neuroscience | Multiple Sclerosis
Share page
Duration 2hrs Milan, Italy
Watch Prof Newsome discuss: Subcutaneous Ocrelizumab in Patients with Multiple Sclerosis: Results of the Phase Ib Dose-Finding OCARINA I Study
Newsome SD, Goldstick L, Townsend B, Figueiredo C, Wolf C,4 Bortolami O, Kletzl H, Bursic L, Schmidt J, Clinch S, Tessaro F, Zecevic D, Bermel R
Neuroscience | Multiple Sclerosis
Share page
03:10 PM
Duration 5mins Milan, Italy
Booth talk slides: Tiptoe if you must, but take a step: Brain Health in clinical practice
Matthias Fuchs and Dr Agne Straukiene
Neuroscience | Multiple Sclerosis - Neuromyelitis Optica
Share page
06:00 AM
Duration 5mins Milan, Italy
Utility and Implementation of a Federated Research Infrastructure to Assess Lack of Disease Stability as a Real-World Surrogate of PIRA, by Combining MS Clinical Trial and Real-World Cohort Data (The INTONATE MS Consortium)
Oh J, Smolders j,Buijs F, Pedotti R, Dahlke F, Kaczmarek L, Kemmisetti A, Sharma V, Heinzmann D, Tackenberg b,Bar-Or A, Wiendl H
Neuroscience | Multiple Sclerosis
Share page
Duration 5mins Milan, Italy
Immune Signatures Associated with Ocrelizumab Treatment in Early Relapsing-Remitting Multiple Sclerosis: New Data on T-Cell Function and Pro/Anti-Inflammatory Monocytes of the 12-Month Interim Analysis from the MA30143 Ocrelizumab Phase IIIb (ENSEMBLE) Immunological Substudy
Wirth T, Schulte-Mecklenbeck A, Steinberg OV, Raposo C, Gross CG, Wiendl H, Klotz L, on behalf of the ENSEMBLE Investigators and Steering Committee
Neuroscience | Multiple Sclerosis
Share page
Duration 5mins Milan, Italy
Kinetics of T-Cell Reactivity and Antibody Responses to SARS-CoV-2 After Different Rounds of Vaccination in Persons With Multiple Sclerosis Treated With Ocrelizumab
Tarkoswki M, Mandelli A, Gabrieli A, Finardi A, Zanetta C, Pedotti R, Raposo C, Rocca M, Moiola L, Filippi M, Riva A, Furlan R
Neuroscience | Multiple Sclerosis
Share page
Duration 5mins Milan, Italy
If time is brain, then it is time for change: Disability prevention in MS
Speakers: Prof. Massimo Filippi, Dr Leorah Freeman, Dr Wallace Brownlee, Dr Riley Bove
Neuroscience | Multiple Sclerosis
Share page
03:00 PM
Duration 120mins Milan, Italy
Fenebrutinib, a Noncovalent, Reversible, Bruton’s Tyrosine Kinase Inhibitor, Potently Blocks Neuroinflammation Induced by FcγR Activation in Human Microglial Systems: Implications for MS Treatment
Julie Langlois, Simona Lange, Jonathan DeGeer, William Macnair, Martin Ebeling, Roland Schmucki, Christopher Harp, Yun-An Shen, Ludovic Collin, Jacqueline A Nicholas, Jiwon Oh, James Keaney
Neuroscience | Multiple Sclerosis
Share page
Duration 120mins Milan, Italy
Low Disability Accumulation After 4-Year Ocrelizumab Therapy in Treatment-Naive Patients With Early-Stage Relapsing-Remitting Multiple Sclerosis: Data From the Phase IIIb ENSEMBLE Study
Patti F, Bermel R, Brochet B, Berger T, Carroll WM, Freedman MS, Holmoy T, Karabudak R, Killestein J, Nos C, Vanopdenbosch L, Vollmer T, Kuenzel T, Kadner K, Kulyk I, Hartung HP
Neuroscience | Multiple Sclerosis
Share page
Duration 120mins Milan, Italy
Analysis of the Adaptive Immune Receptor Repertoire Alongside Treatment with Ocrelizumab
Schneider-Hohendorf T, Rubelt F, Mirebrahim H, Asgharian H, Wünsch C, Schulte-Mecklenbeck A, Lohmann L,Tackenberg B, Raposo C, Gross CC, Klotz L, Wiendl H, Schwab N
Neuroscience | Multiple Sclerosis
Share page
Duration 120mins Milan, Italy
Persistence to Ocrelizumab Compared with Other Disease-Modifying Therapies for Multiple Sclerosis in the German NeuroTransData Registry
Braune S, Dirks P, Colloud S, Davies E, Wang Q, Heer Y, Zürcher M, Sun D, NTD Study Group
Neuroscience | Multiple Sclerosis
Share page
Duration 120mins Milan, Italy
Unsupervised Analysis Reveals That Memory IgA B Cells are Spared by Ocrelizumab Treatment
Garcia A, Dugast E, Lebrun-Frenay C, Thouvenot E, De Seze J, Le Page E, Vukusic S, Maurousset A, Berger E, Casez O, Labauge P, Ruet A, Raposo C, Lefrère F, Nicot A, Wiertlewski S, Gourraud P-A, Berthelot L, Laplaud DA
Neuroscience | Multiple Sclerosis
Share page
10:35 AM
Duration 7mins Scientific Session 20: Female Health
Disease Activity During Pre-Conception, Pregnancy and Postpartum in Women with MS Receiving Ocrelizumab or Other Disease-Modifying Therapies in a Real-World Cohort
Yeh W, van der Walt A, Skibina O, Kermode A, Marzena P, Kalincik T, Lechner-Scott J, Alroughani R, Boz C, John N, Buzzard K, Hodgkison S, Macdonell R, Van Pesch V, Laureys G, Van Hijfte L, Willekens B, Prevost J, Prat A, Girard M, Duquette P, Habek M, Baghbanian S, Ozakbas S, Horakova D, Havrdova E, Karabudak R, Patti F, Yamout B, Khoury S, Barnett M, McCombe P, Foschi M, Terzi M, Maimone D, Gerlach O, Altintas A, Blanco Y, Hughes S, Jose Sa M, Grammond P, La Spitaleri D, de Gans K, Gouider R
Neuroscience | Multiple Sclerosis
Share page
Duration 5mins Milan, Italy
The future is now: Paving the path for precision in neuroimmunology
Speakers: Prof. Amit Bar-Or, Prof. Jacqueline Palace, Prof. Sarah A. Morrow
Neuroscience | Multiple Sclerosis
Share page
02:03 PM
Duration 7mins Scientific Session 22: Late Breaking Abstracts
Cerebrospinal Fluid and MRI Analyses of Fenebrutinib Treatment in Multiple Sclerosis Reveal Brain Penetration and Early Reduction of New Lesion Activity: Results from the Phase II FENopta study
Amit Bar-Or, Michal Dufek, Hrvoje Budincevic, Jelena Drulovic, Mario Habek, Le H Hua, Martin S Weber, Piia Thomas, Julie Napieralski, David Clayton, Denison Kuruvilla, Qi Qi, Yan Xu, Alexandra Goodyear, Jiwon Oh
Neuroscience | Multiple Sclerosis
Share page

© 2024 Genentech USA, Inc. All rights reserved. This site is intended for US HCPs only.

Learn more about MEDICALLY